The Asia-Pacific Journal of Ophthalmology

Asia-Pacific Journal of Ophthalmology:

Issue 6, November/December 2017 Review Article

Anti–Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization

Ng, Danny S.C.; Lai, Timothy Y.Y.; Cheung, Chui Ming Gemmy; Ohno-Matsui, Kyoko

Author Information

From the *Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong; †2010 Retina and Macula Centre, Hong Kong; ‡Singapore Eye Research Institute, Singapore National Eye Centre; §Duke NUS Medical School, National University of Singapore, Singapore; and ¶Department of Ophthalmology and Visual Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Reprints: Timothy Y.Y. Lai, MD, FRCSEd, FRCOphth, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 4/F Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong. E-mail:


Myopic choroidal neovascularization (CNV) is one of the most vision-impairing complications in patients with pathologic myopia. It is also one of the most frequently encountered non‒age-related macular degeneration causes of CNV and affects young patients in the working age group. Fluorescein angiography (FA) and spectral domain optical coherence tomography (OCT) are generally indicated to confirm the diagnosis of active myopic CNV before initiation of treatment. Without treatment, natural history studies have shown that the vision outcome can be very poor. More recently, a number of retrospective, prospective and phase 3, multicenter, randomized controlled trials have established the safety and efficacy of intravitreal anti‒vascular endothelial growth factor (VEGF) agents for the treatment of myopic CNV. Long-term follow-up studies have found that some of the initial vision gained after intravitreal anti-VEGF therapy may not be maintained, owing to the presence and progression of chorioretinal atrophy (CRA) adjacent to the CNV. Further research on clinical and imaging characteristics may elucidate the prognostic factors that are crucial to optimizing the treatment and prevention of visual impairment associated with myopic CNV.

Full Text

View PDF Online

Download PDF

APJO Express

More About APAO

  • 1
  • 2
  • 3
  • 4
< >
All Rights Reserved © Asia-Pacific Academy of Ophthalmology